Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


OTCPK:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Legal Action
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(169)
•••
Comment by mstrmndon Jun 01, 2020 11:43am
274 Views
Post# 31096579

RE:RE:Legal Action

RE:RE:Legal ActionI've been watching this stock for over 5 years and have seen what's happening on the daily...

The behaviour of this SP shows significant manipulation...Why don't I just get 20 weathy doctors and lawyers to sell, cause an avalanche and buy back in just because it benefits me and my ring?  The company has been significantly harmed by these individuals...  

Several lawyer friends of mine are watching this closely...Today's paradoxical behaviour for a small ring looking to benefit preferentially could cost them everything...

The flip side is...incredible time to buy...however 12.5M shares and counting should be sold at $1.40 plus had it not been for this ring that caused a fake avalanche this morning


Marky1 wrote: You are brilliant! Thank u


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities